- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05336084
Circadian Rhythms and Homeostatic Sleep Drive and Their Effect on Reward and Cognitive Control Systems in Adolescents (CARRS-P1)
April 19, 2023 updated by: Peter Franzen, University of Pittsburgh
Center for Adolescent Reward, Rhythms and Sleep Project 1
Adolescence is a time of heightened reward sensitivity and greater impulsivity.
On top of this, many teenagers experience chronic sleep deprivation and misalignment of their circadian rhythms due to biological shifts in their sleep/wake patterns paired with early school start times, which may increase the risk for substance use (SU).
However, what impact circadian rhythm and sleep disruption either together or independently have on the neuronal circuitry that controls reward and cognition, or if there are interventions that might help to modify these disruptions is unknown.
Project 1 (P1), specifically examines homeostatic and circadian characteristics as mechanisms linking habitual sleep patterns, reward and cognitive control (at subjective, behavioral, and circuit levels), and longitudinal substance use risk.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
P1 will study 96 adolescents ages 13-15, stratified by habitual sleep timing (early, intermediate, late), in a 60-h laboratory study.
Participants will monitor sleep patterns at home for 2 weeks with actigraphy and sleep diary, and will also complete fMRI measures of reward and cognitive control.
This will be followed by a 60-hour laboratory visit.
The laboratory session includes two nights of polysomnography (PSG) sleep studies, separated by 36 h of an ultradian sleep/wake protocol-every 120-minutes, there will be an 80-minute period of waking, followed by a 40-minute sleep opportunity.
Participants will be in dim light conditions and temporal isolation for the first 24 h of the ultradian sleep/wake protocol.
Physiological circadian measures include salivary melatonin; core body temperature (CBT); and molecular rhythms from hair follicle cells (examined in Project 3).
Physiological sleep homeostatic measures include waking EEG theta power, slow-wave sleep rebound following the 36-h ultradian sleep/wake protocol, and repeated sleep latency on the sleep opportunities.
Behavioral tests (Reward Anti-Saccade task to index cognitive control with/without reward modulation; Psychomotor Vigilance Test) and self-reports of mood/sleepiness will be collected every 2 h.
Longitudinal on-line surveys will assess substance use every 6 months for the life of the grant.
Study Type
Interventional
Enrollment (Anticipated)
96
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ronette Blake, MS
- Phone Number: (412) 443-3704
- Email: blakerg2@upmc.edu
Study Contact Backup
- Name: Sarah Aerni
- Phone Number: 412-551-110
- Email: aernise2@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- Western Psychiatric Hospital
-
Contact:
- Ronette Blake, MS
- Phone Number: 412-443-3704
- Email: blakerg2@upmc.edu
-
Principal Investigator:
- Peter L. Franzen, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years to 15 years (Child)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 13-15 years
- Currently enrolled in a traditional high-school (not cyber- or home-schooled) [school closures during the COVID-19 pandemic are an exception to this]
- Physically and psychiatrically healthy
- Provision of written informed consent and assent
Exclusion Criteria:
- outside age range above
- have a history of alcohol, cannabis, or illicit drug use in the past month, or greater than monthly use in the past year
- have serious medical or neurological disorders, including history of seizures
- have serious psychiatric disorders (e.g. bipolar disorder and schizophrenia)
- taking antidepressants (SSRIs/SSNIs are OK) or medications known to impact sleep/wake function - some medications may be okay if willing and able to discontinue prior to and/or for laboratory procedures
- have sleep disorders other than insomnia or Delayed Sleep Phase Disorder
- have MRI contraindications (i.e., metal in the body; claustrophobia)
- first degree relative with bipolar disorder
- frequent headaches or migraines
- inability to swallow pills/capsules.
- pregnancy
- participants with observed Obstructive Sleep Apnea via Apnealink, as indicated by an Apnea Hypopnea Index (AHI) of greater than 5
- Less than 80 lbs. or a BMI of greater than 35
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ultradian Sleep/Wake protocol
This study uses an ultradian sleep/wake protocol to examine circadian and homeostatic sleep systems and their contributions to reward and cognitive control function.
All participants will undergo the ultradian sleep/wake protocol following a night of sleep in the lab (measured with polysomnography) for 36 hours.
The ultradian sleep/wake protocol will last for 36 h, during which every 120-minutes, there will be an 80-minute period of waking, followed by a 40-minute sleep opportunity.
A repeat night of sleep will occur at the end of the 36-hour ultradian sleep/wake protocol.
|
120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in EEG delta power across overnight polysomnography on the night preceding vs. following the 36-hour ultradian sleep/wake protocol.
Time Frame: The first night of sleep preceding the 36-hour ultradian sleep/wake protocol vs the night of sleep following the ultradian sleep/wake protocol
|
Change in the slope of EEG delta power (0.5 - 4 Hz) across NREM periods (frontal leads) on the night preceding vs. following the 36-h ultradian sleep/wake protocol (as measured by polysomnography).
|
The first night of sleep preceding the 36-hour ultradian sleep/wake protocol vs the night of sleep following the ultradian sleep/wake protocol
|
Change in slope of waking EEG theta power
Time Frame: Every 2 hours during the 36-hour ultradian sleep/wake protocol
|
Assessed every 2 hours across the 36-hour ultradian sleep/wake protocol
|
Every 2 hours during the 36-hour ultradian sleep/wake protocol
|
Melatonin onset
Time Frame: The first 24-hours of the ultradian sleep/wake protocol
|
Endogenous circadian phase estimate of the rise in evening melatonin levels from saliva samples collected over a 24-hour period (every 30 - 60 minutes) under dim light conditions.
|
The first 24-hours of the ultradian sleep/wake protocol
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Circadian pattern of Core Body Temperature (CBT)
Time Frame: Measured continuously across the 36-hour ultradian sleep/wake protocol.
|
Minimum of CBT
|
Measured continuously across the 36-hour ultradian sleep/wake protocol.
|
Melatonin amplitude
Time Frame: Collected every 30-60 minutes across the first 24-hours of the ultradian sleep/wake protocol
|
Amplitude of the 24-hour melatonin period to estimate endogenous circadian phase
|
Collected every 30-60 minutes across the first 24-hours of the ultradian sleep/wake protocol
|
Sleep latency
Time Frame: During the 40-minute sleep opportunities collected every two hours across the 36-hour ultradian sleep/wake protocol.
|
Time until sleep onset (first 30-second epoch of N2 sleep) as assessed by polysomnography
|
During the 40-minute sleep opportunities collected every two hours across the 36-hour ultradian sleep/wake protocol.
|
Influence of sleep and circadian measures on neural correlates of impulse control
Time Frame: Measures from the 36-hour ultradian sleep/wake protocol in relation to an fMRI scan measured 1 to 2 weeks earlier.
|
This outcome will be measured during the Stop Signal Task, which is a computerized an fMRI behavioral task.
It will be assessed by activation within the Executive Control Network, specifically, activation is defined as bold signal in regions of the Executive Control Network (particularly the inferior frontal gyrus) on correct Stop trials versus correct Go trials.
|
Measures from the 36-hour ultradian sleep/wake protocol in relation to an fMRI scan measured 1 to 2 weeks earlier.
|
Influence of sleep and circadian measures on neural correlates of reward anticipation and reward outcome.
Time Frame: 1 to 2 weeks before to immediately after the 36-hour ultradian sleep/wake protocol.
|
This outcome will be measured during the Money Incentive Delay Task, which is a computerized an fMRI behavioral task.
It will be assessed by activation within the reward network, specifically, activation is defined as bold signals in regions of the reward network (particularly the ventral striatum) on reward anticipation trials versus no money trials.
|
1 to 2 weeks before to immediately after the 36-hour ultradian sleep/wake protocol.
|
Performance on the Psychomotor Vigilance Task
Time Frame: 1 to 2 weeks before to immediately after the 36-hour ultradian sleep/wake protocol.
|
This outcome will be measured during the Psychomotor Vigilance Task, specifically lapses (reaction times > 500 ms) on this sustained attention task.
|
1 to 2 weeks before to immediately after the 36-hour ultradian sleep/wake protocol.
|
Performance on the Reward Anti-Saccade task
Time Frame: Measures collected every two hours during the 36-hour ultradian sleep/wake protocol.
|
This outcome will be measured during the Reward Anti-Saccade task, which measures the ability to look away from a target (an anti-saccade).
|
Measures collected every two hours during the 36-hour ultradian sleep/wake protocol.
|
Substance use
Time Frame: Every 6 months for the duration of the study, up to 4.5 years
|
Frequency-based self-reports of substance use.
|
Every 6 months for the duration of the study, up to 4.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2022
Primary Completion (Anticipated)
March 31, 2025
Study Completion (Anticipated)
June 30, 2025
Study Registration Dates
First Submitted
August 31, 2021
First Submitted That Met QC Criteria
April 14, 2022
First Posted (Actual)
April 20, 2022
Study Record Updates
Last Update Posted (Actual)
April 20, 2023
Last Update Submitted That Met QC Criteria
April 19, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- STUDY20030237
- P50DA046346 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Current and future investigators, both internal and external, may have access to de-identified data; however only group data would be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionEnrolling by invitation
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, Wisconsin; Divine Savior...Active, not recruitingSleep | Sleep HygieneUnited States
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruiting
-
Brain Electrophysiology Laboratory CompanyCompletedSleep | Sleep HygieneUnited States
-
Aretaieion University HospitalRecruitingSleep Disorder | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Surgery | Anesthesia | Sleep Fragmentation | Sleep Disorders, Circadian RhythmGreece
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
Clinical Trials on Ultradian sleep/wake protocol
-
Brigham and Women's HospitalActive, not recruitingPhysiologyUnited States
-
Applied CognitionUniversity of Florida HealthCompleted
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityRecruitingSleep Disorders, Intrinsic | Sleep Wake Disorders | Sleep Disorders, Circadian Rhythm | Advanced Sleep Phase Syndrome (ASPS) | Delayed Sleep Phase Syndrome | Shift-Work Sleep Disorder | Delayed Sleep Phase | Non-24 Hour Sleep-Wake Disorder | Advanced Sleep Phase Syndrome | Advanced Sleep Phase | Irregular... and other conditionsUnited States
-
National Institute on Aging (NIA)Brigham and Women's HospitalCompleted
-
University of AarhusCompleted
-
University of OstravaUniversity Hospital Ostrava; General University Hospital, PragueRecruiting
-
University of Missouri-ColumbiaCompleted
-
University of UtahCompletedDelirium | Sleep DeprivationUnited States
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR); Children's Hospital Medical...Completed
-
University of Massachusetts, AmherstUnknownSleep | Age | Emotional ValenceUnited States